SCH-530348
![]() | |||
(IUPAC) ime | |||
---|---|---|---|
Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate | |||
Klinički podaci | |||
Identifikatori | |||
CAS broj | 618385-01-6 | ||
ATC kod | B2C | ||
PubChem[1][2] | 10077130 | ||
Hemijski podaci | |||
Formula | C29H33FN2O4 | ||
Mol. masa | 492.58 g/mol | ||
| |||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status |
SCH-530,348 je antagonist trombinskog receptora (PAR-1). On je baziran na prirodnom proizvodu himbacinu. Razvila ga je kompanija Šering-Plau (engl. Schering-Plough). SCH-530,348 je potentan lek za akutni koronarni sindrom, bol u prsima uzrokovan koronarnom bolešću arterija.[3]
Ovaj lek je prešao u vlasništvo kompanije Merk (engl. Merck). On je poznat pod imenom Vorapaxar.
Literatura
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Samuel Chackalamannil (2008). „Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity”. Journal of Medicinal Chemistry 51: 3061. DOI:10.1021/jm800180e.
Spoljašnje veze
![]() | Portal Medicina |
![]() | Portal Hemija |
- C&EN
- ChemSpider